Table 1 Evaluation and follow-up of HT-1 patients identified by newborn screening

From: Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations

Evaluation

Initiation of therapy (baseline)

First year of life

From 1 year to 5 years of age

After 5 years of age

  

Monthly

Every 3 months

Every 3 months

Every 6 months

Yearly

 

HT-1 markers

 Blood succinylacetonea (plasma/ blood on filter paper)

x

xb

 

x

  

Every 6 months

 Urine succinylacetone (only if blood is not available)

x

x

 

x

  

Every 6 months

 Blood NTBC concentrationa

 

x

 

x

  

Every 6 months

 Plasma amino acids (plasma/blood on filter paper)

x

xb

 

x

  

Every 6 monthsc

Laboratories for HT-1 monitoring

 CBC: hemoglobin, hematocrit, WBC, platelet count

x

 

x

  

x

Yearly

Liver evaluation

 Serum AFP concentration

x

x

  

x

 

Every 6 monthsd

 PT

x

xe

   

x

Yearly

 PTT

x

xe

   

x

Yearly

 ALT/AST

x

 

xe

  

x

Yearly

 Imaging: CT or MRI (with contrast) or ultrasoundf,g

x

    

xc

Yearlyc

Renal studies

 Renal imaging (ultrasound)h

x

      

 Blood chemistries: bicarbonate, BUN, creatinine

x

    

x

Yearly

 Blood calcium and phosphate

x

    

x

Yearly

 Urine analysis

x

      

Standard dietary management laboratories: if not included above, see text for more information

Developmental evaluation/ neuropsychology assessment

      

Before school age

Ophthalmology: slit-lamp examination

When symptomatic or at increased risk (see text for more information)

  1. AFP, α-fetoprotein; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NTBC,2-[2-nitro-4-trifluoromethylbenzoyl]-1,3-cyclohexanedione; PT, prothrombin time; PTT, partial thromboplastin time; WBC, white blood count.
  2. Nominal group recommendation: 56% strongly agree and 44% agree.
  3. aPhysician has choice of blood NTBC or SA.
  4. bCan switch to filter paper monitoring if the same is used over time for the baseline.
  5. cAs needed based on compliance.
  6. dAny increase, immediate imaging.
  7. eUntil normal.
  8. fNeed to wait 1 week post initiation of NTBC treatment to avoid anesthetic-induced porphyric crisis.
  9. gUltrasound: validity is operator-dependent.
  10. hWhile doing liver imaging, and then only as clinically indicated after this.